GLP-1R Agonist Treatment for Opioid Use Disorder — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GLP-1R Agonist Treatment for Opioid Use Disorder — Stella

Home/Opioid Use Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Opioid Use Disorder trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

University of Maryland Baltimore, Baltimore, Maryland

NYU Langone Health, New York, New York

Pennsylvania Psychiatric Institute, Harrisburg, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Milton S. Hershey Medical Center

Collaborators

New York University, University of Maryland

Enrollment target

~200 participants

Started

January 2025

Primary completion

November 2026

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.